New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 27, 2014
07:03 EDTBLUEBluebird Bio announces first patient transplanted in Phase 1/2 Northstar study
bluebird bio announced that the first subject with beta-thalassemia major has been enrolled in its phase 1/2 Northstar Study -- HGB-204 -- in the United States and has undergone infusion with bluebird bio’s LentiGlobin drug product in an autologous hematopoietic stem cell transplantation. The phase 1/2 study is designed to evaluate the feasibility, safety and efficacy of LentiGlobin drug product in the treatment of subjects with beta-thalassemia major. The study is designed to enroll up to fifteen subjects. Subjects will be evaluated for safety and efficacy post-transplant.
News For BLUE From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 26, 2015
06:33 EDTBLUEbluebird bio price target raised to $119 from $112 at Piper Jaffray
Piper Jaffray raised its price target for bluebird bio to $119 following the company's Q4 results and reiterates an Overweight rating on the name. Piper sees 2015 as a "big year" for bluebird with preliminary sickle cell data.
February 25, 2015
16:03 EDTBLUEbluebird bio reports Q4 EPS (67c), consensus (57c)
Subscribe for More Information
February 23, 2015
07:22 EDTBLUESunTrust to hold a conference
2015 Biotechnology and Pharmaceutical 1:1 Orphan Drug Day is being held in New York on February 23.
February 19, 2015
07:12 EDTBLUEWharton Health Care Club to hold a conference
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use